Shares in Santhera Pharmaceuticals Holding AG plunged 40 percent last week on news that its lead compound Catena (idebenone) missed the primary endpoint in a U.S. Phase III trial in patients with Friedreich's Ataxia. (BioWorld International)
Oxford BioTherapeutics (OBT) Ltd. entered its first big pharma drug discovery and development deal, a potential $370 million pact with GlaxoSmithKline plc to develop antibody therapies against cancer. (BioWorld International)
No Abstract BioWorld International CorrespondentDeveloGen AG is getting an up-front payment of €7 million (US$9.52 million) and could earn as much as €237 million more in milestone payments from Boehringer Ingelheim GmbH, in return for a novel drug target for Type II diabetes and other metabolic diseases, a series of chemical leads and associated intellectual property and know-how.
